Dyspnea rituximab

A wide range of adverse events has been reported in most patients (5). A transient flu-hke syndrome is very common (50-90%), particularly after the first infusion of rituximab, and is often associated with various hypersen-sitivity-hke symptoms (5-20%). In the most severe cases, patients had hfe-threatening cytokine release syndrome with dyspnea, bronchospasm, hypoxia, hypotension, urticaria, and angioedema. Deaths have been reported in eight of 12 000-14 000 patients after drug launch. 

In general, the MoAbs used in treating cancer are relatively well tolerated compared with conventional cytotoxic chemotherapy. The main adverse effect associated with rituximab use is infusion-related or hypersensitivity reactions. Patients may experience fever, rigors, dyspnea, hypotension, and rarely anaphylactoid reactions. Premedication with acetaminophen, diphenhydramine, and corticosteroids can reduce these reactions. Patients with significant tumor burden at the time of first treatment with rituximab may experience tumor lysis syndrome, and appropriate measures should be implemented to prevent this complication in these patients. 

Rituximab ADCC CDC apoptosis 375 mg/ra IV infusion weekly for 4 weeks Infusion-related toxicity with fever, rash, and dyspnea B-ceU depletion late-onset neutropenia... 

A teenage boy with focal segmental glomerulosclerosis developed rituximab-associated lung injury associated with progressive dyspnea, fever, hypoxemia, and fatigue 18 days after the completion of a second course of rituximab infusion for calcineurin inhibitor-dependent nephrotic syndrome [150 ]. 

Respiratory Cases of interstitial lung disease, dyspnea, and pneumonitis associated with rituximab, some fatal, have been reported [282 , 283, 284, 285, 286 287. ... 

---